Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think OWCP is setting up and acting to much like a large pharma company for any Canadian company to have the capital to actually purchase them. No big pharma companies in Canada... now could a deal be made to produce product there... definitely.... on another thought... since OWCP isn't pursuing the cosmetic cream side there shouldn't be a reason to worry about listing on the CSE and I would hope they would revisit this.
I think there are a couple things to remember. 1- NTVA has never done any PR campaigns. 2- there are currently less then 10Million shares actually trading 3-Though some sole during the private placement I'm not sure anyone is willing to let go of shares this early on with what is coming throughout this year at these prices. Once on the CSE and the remainder of the private placement shares are available I think we will see higher volume and higher prices. Right now very very few know of NTVA and I think the company wants it that way for the moment.
Year in closing filing due mid september. Class D warrants for 1 dollar end of september. More private placement shares mid october. Possibly mid november or december CSE uplisting. January class E warrants at 2 bucks. I expect we will hear phase one trials in process or complete, favorable results and moving to phase 2 in germany. Likely EU exchange listing somewhere in there also.
To much volume above .18 today. The more shares that are traded above .18 the stronger the resistance. I don't see it going below .18 today... And it would take a purposeful effort to drop it below there over next week. (likely favorable news tonight or monday before open)
Not going to tell anyone what to do but normally from what I've seen... big spike in the morning... cool off during lunch to let flippers outs and then nice end of the day finish. We could likely retest .18 as support now during mid day but I see us moving up nicely off of that and continuing next week. Hopefully the commitment during the wallstreet presentation "to bring exceptional value for shareholders" is starting.
INTIVA BioPharma (OTCQB-NTVA) Files a Listing Application with the Canadian Securities Exchange (CSE)
The CSE listing, when approved, will increase Intiva BioPharma’s visibilty in the international financial community and help attract interest from global investors
DENVER, CO / ACCESSWIRE / August 22, 2018 / INTIVA BioPharma Inc. ("INTIVA" or the "Company") (NTVA) announced today that it has filed a preliminary non-offering prospectus with certain securities regulators in Canada and has filed a listing application to list its commonshares withthe Canadian Securities Exchange (“CSE”).
Intiva BioPharma’s shares currently trade on the OTCQB market in the United States, and upon approval of the CSE listing will trade both in the U.S. and Canada.
In announcing the CSE listing application, Alain Bankier, INTIVA BioPharma’s Interim CEO, said, "Cannabinoid pharmaceutical development is increasingly becoming a global activity. Consistent with this trend, we recently announced that Germany-based, Dr. Benedikt Schoser was retained as an advisor to INTIVA. Dr. Schoser is a world-renowned expert on the molecular mechanisms of muscle loss and weakness, and myotonic dystrophy, conditions for which INTIVA previously filed a patent application in the U.S.”
Bankier also stated, “Since Toronto has become the world financial center for cannabis and cannabinoid pharma-related financings, it became clear that a Canadian stock market listing would be beneficial for INTIVA in potentially accessing capital from global investors and developing increased trading activity of the Company’s shares.”
About INTIVA BioPharma Inc:
INTIVA BioPharma is a US-based pharmaceutical development company engaged in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration ("FDA") pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.
INTIVA BioPharma's drug development strategy consists of:
1. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;
2. Conducting "freedom to operate" investigations on these conditions;
3. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;
4. Identifying the regulatory pathway with the FDA; and
5. Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).
Current financial disclosure and Real-Time Level 2 quotes for Intiva BioPharma are available at www.otcmarkets.comor at www.INTIVABioPharma.com.
The listing of the Company’s common shares on the CSE is subject to acceptance by the exchange. There are no assurances that acceptance will be granted. Listing on the CSE is subject to certain conditions including that the Company receives a receipt for a final prospectus filed with certain securities regulatory authorities in Canada.
INTIVA Disclosure Notice: This press release contains "forward-looking statements. For this purpose, any statements contained herein or which are otherwise made by or on behalf of INTIVA BioPharma that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties, which may cause results to differ materially from those, set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; INTIVA BioPharma's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to events outside of INTIVA BioPharma's control.
Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. INTIVA BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
Boom Time Cometh.... September should be interesting. We will have the 10K for the year in review which honestly should have some great information being that it is the first truly SEC regulated document to be released and will likely contain follow up from the requested meeting with the FDA... or at least if they were granted the meeting.
Yes this is speculation but 1 dollar warrants available for purchased in September and 2 dollar warrants in January. Could be wrong but looks promising to me and nice additions to business plan and directors)
Agree completely. Private placement holders had the opportunity to sell at a very high market cap for a company which even being speculative with such great potential and leadership was overvalued for what information is known. I do expect there is a lot more that has happened with the company and will be released soon.
Also 10k will be out in September. Fiscal year ended in June. (I asked if we were going to receive a 10Q so only reason I know.) This is also around the time that more private placement shares will be released. With class D and E warrants being priced where they are... I would expect that much will be disclosed in the upcoming months.
As always do your own D&D but I also experienced odub pain. He does own a large number of shares but has no influence in the leadership and I don't see that ever reversing. The number of shares he owns in his name would require him to notify the SEC (though he does have some through other entities which would not require that)
NTVA is taking a 3 prong approach (One being buying IP/research from other companies) and early this year (Feb I believe) requested a meeting with the FDA regarding a treatment for chemical warfare. The main amount of shares will be released in September for those with private placement. I can't say what people will do but as a private placement holder I personally exchanged my class C warrants for class D and E execrable at 1 dollar in September and 2 dollars in January 2018 and admittedly have added in about 50k shares in the last month. I personally believe this paints a picture of where the company plans to be for market cap and time frame wise.
I personally feel that though ODub current leadership team is strong that NTVA is just as strong and understands the balance of investor sentiment and bringing actual value to market much better. I also believe that some of those who are in leadership of NTVA where/are investors in ODub and have seen the importance of taking a different approach while being founded in research and truly looking towards being a huge organization in the future.
He was. That said his influence is nothing now and the team in place have remarkable credentials.
No one knows about NTVA right now. There has been no marketing campaigns or anything. This will need to happen after they have significant news to release and can justify a higher market cap. Until then it looks like we will hang around these levels unless someone who does know about NTVA wishes to buy more higher or sell some lower.
TD told me no but Fidelity did for me. Not sure what changed.
My understanding is that the class c's can be traded in for the class D and E warrants exercisable at 1.00 and 2.00 respectively.
Hate to say it but I would agree. I do believe OWCP current leadership is moving things along but their is a price to pay for the foolishness from a few years ago and that ground has to be made up. I think we are but in the would of pharma a few missed years is a few years of ground to cover. I don't look for OWCP to really be ready to reach it's potential until mid to late 2020. When and if it does then those who acquired in this level will be thankful. For those who put money here... a lot has left to be taken care of else where. Though mine has remained I have not added but I will continue to hold my shares also.
I would agree. I think there are big things in the near future. Personally I opted for the class D and E warrants and secured another 30k+ shares already over the last few weeks.
OWC Pharmaceutical Research Corp Initiated Final Stage of Cannabinoid-based Topical Ointment Safety Study
PR Newswire
RAMAT GAN, Israel, August 1, 2018
RAMAT GAN, Israel, August 1, 2018 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today the initiation of the final stage of its Phase I, placebo controlled, maximal dose study (the "Psoriasis Study") to determine the safety and tolerability of topical ointment containing medical grade cannabis in healthy volunteers. On June 28, 2018, the Company announced that it had successfully completed the initial stage of this trial, which comprised the single dosing of healthy volunteers. The final stage of the trial comprises the twice daily dosing of healthy volunteers for 6 weeks. The study is being performed by Professor Aviv Barzilai, Director of the Department of Dermatology at Chaim Sheba Medical Center. Sheba is a university-affiliated hospital that serves as Israel's national medical center and is one of the leading integrated medical centers in the Middle East.
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
Mr. Mordechai Bignitz, the Chief Executive Officer of OWC commented, "We mentioned in our recent letter to shareholders that we were waiting for licenses in order to initiate this trial. This approval has now been obtained and we will immediately initiate clinical testing. Validation of safe and efficacious therapeutics is key to our mission and we aim to progress our studies as rapidly as possible, adhering to best clinical practices."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
Contact:
Mordechai Bignitz
Chief Executive Officer - OWC Pharmaceutical research crop,
Email: Mordechai.Bignitz@owcpharma.com
Tel: +972-(72)-260-8004
I would agree. Hoping for news soon
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
https://www.streetinsider.com/SEC+Filings/Form+4+Intiva+BioPharma+Inc.+For%3A+Jul+25+Filed+by%3A+Bankier+Alain+D/14437352.html
Totally agree with Renegades17. Love that your asking questions but BioPharma on OTC is an odd beast... it's not a normal OTC and it's not a developed company. It's like buying into MicroSoft in 1994 because you knew the potential Windows 95 was going to have.... which it didn't even truly realize it's potential until like 97.
Beyond that I fully suspect we hear about what the company has been up to for the last year and a half over the next 4 months or so.
Why do people keep saying merger or acquisition. There is absolutely no evidence of this from what I've see or heard. If you know then please share.
Interesting... hadn't been watching the yield curve that close but was feeling things were starting to have a little shakiness. I do think OWCP is positioned well and could see growth. My goal and hope is to see them with revenue to sustain the R&D side and essentially self-fund their research for licensing deals which is where the money will be made. Though we could see a large down turn some of the mega pharm and other companies like Amazon for instance are sitting on a ton of cash. I believe Amazon is nearly 1 trillion in cash reserves. With their entry into the MCO would and pharma delivery service it's only a matter of time until they start buying and manufacturing pharma products.
Shermann while I completely agree with you. 500% from here is only a buck.
Looking at OWCP's timeline for 2 years I expect multi-dollars as they will be in stage 3 clinical trials at that time and depending on what point in 2020 you are thinking may have completed stage some of stage 3. I fully expect for there to be revenue well before then from the cosmetic line of topical cream and possible licensing deal from the tablet. I strongly suspect we will be multi-dollars by end of q3 2019 at the very latest as they will have completed stage 2 trials on multiple product lines.
Looks like all the market makers are accumulating slowly and holding the price rather stable for the moment. At least that is what I see from the L2
INTIVA BioPharma Inc (NTVA) Begins Trading on the OTCQB Venture Market
DENVER, CO / ACCESSWIRE / July 19, 2018 / INTIVA BioPharma Inc. ("INTIVA" or the "Company") (OTCQB: NTVA) today announced today that its stock started trading on the OTCQB market with the symbol NTVA after a successful upgrading from the OTC Pink market.
Alain Bankier, the Company's Interim CEO, said, "We are very pleased that OTC Markets has accepted our Company into the OTCQB Venture Market. This is a reflection of our ongoing objective to provide additional visibility and credibility to the investment community, as we continue to build INTIVA BioPharma to advance the science of cannabinoid-based and Food and Drug Administration (FDA)-compliant medicine."
Investors can find current financial disclosure and Real-Time Level 2 quotes for this company on www.otcmarkets.com or on www.INTIVABioPharma.com.
About INTIVA BioPharma Inc:
INTIVA BioPharma is a US-based pharmaceutical development company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration ("FDA") pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.
INTIVA BioPharma's drug development strategy consists of:
The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;
Conducting "freedom to operate" investigations on these conditions;
The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;
Identifying the regulatory pathway with the FDA; and
Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).
INTIVA BioPharma website: www.intivabiopharma.com.
About OTC Markets Group Inc.:
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX Best Market, the OTCQB Venture Market and the Pink Open Market for 10,000 U.S. and global securities. Through OTC Link ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. OTC Markets enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
INTIVA Disclosure Notice: This press release contains "forward-looking statements. For this purpose, any statements contained herein or which are otherwise made by or on behalf of INTIVA BioPharma that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties, which may cause results to differ materially from those, set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; INTIVA BioPharma's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of INTIVA BioPharma's control.
Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. INTIVA BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
Company Contact:
Mark Lubchenco
Director of Investor Relations
INTIVA BioPharma Inc.
303 495 7583
mlubchenco@intivabiopharma.com
www.INTIVABioPharma.com
SOURCE: INTIVA BioPharma Inc.
7/19/2018 8:00:00 AM
There is no evidence or a merger or acquisition. If you find proof then please provide. Just as I don't like the nay sayers it's silly to think this would be a target for either one other than a hostile take over. They need to prove their research and we should have that by the end of Q3. I know for a fact that discussions are being held to license out the cream for production. I know this not from OWCP but because I know people who are shareholders who have been reaching out to other companies trying to put the golden egg in OWCPs lap gift wrapped.
So much more potential here then what it is at and only time will tell if OWCP leadership is to become the industry leader in MMJ research and license out it's products. As of today it's not looking great but I'm still holding because I do believe this company is much more valuable than what it's trading at today.
Good find. Friedland selling to pay for court cost. All I can say is slime ball.
I think most who have shares right now are long holders. Yes there are shorters and flippers but the volume is really down from the historical side and not a lot of longs will sell at these prices. Just my opinion but I think most fence sitters are waiting for a licensing deal and for revenue.
These are great prices. Looks like liquidity is tight again which should lead to nice squeezes as news is released.
I'm still a firm believer they will try to be well over 50 cents a share before the end of the month. Makes no sense to purchase last round of warrants at that price when shares can be purchased for less and no seasoning period.
Overall great company but as of right now as far as we (public) know this is a early stage company with great potential. News about how the FDA meeting went and any contract or licensing deal (which are possible) would see a nice PPS increase.
As a private placement I'm holding and have not sold. I firmly believe we have not had news in 1.5 years on the progress of things so there was a ton of news to release when shares started free trading. I know the company had originally targeted 6 months to have free trading shares so I'm sure they looked to have news available that soon and have been sitting on it. (Just my opinion)
Smart Person for sure than. Penny Land takes a strong stomach.
Great team here and definitely a lot of potential. Hoping to hear news from the last 1.5 years of new developments so the potential becomes reality.
Class B was not extended and has closed. Class C is still same date in July as of right now. I think a big reason for the repeated extensions is because the private placement holders did not have access to any shares after 1.5 years. That's a long time to have invested in something and not be able to sell anything or have control over that investment. With that said at least for myself I was not going to invest in the Class B round without having access to my shares. The Class C will not happen for me if we are not at least 1.50 or higher on the date the warrants are able to be purchased. I have enough shares... but why pay the same price as open market and be restricted for 6 months or more. Just my thoughts... others may feel differently.
I could see this being the case but only the company knows the timeline for releasing these updates.
I'm hoping that is true. I do think we could hear a deal with a military (Israel?) for the chemical warfare treatment.
EU and FDA have agreed to allow selling of product and for either country as long as they are being manufactured in one of those countries. This is several year old agreement. I think it's a good move. Germany is a hot bed for some great medical and pharma companies. So I think it's a smart move and it looks like they added a heck of an expert.
Respectful Spirited Debate is good. I can say I am a private placement holder but won't be selling in this range. From established networks with some of the other private placement holders... I have heard they are't even moving their shares from the holding firm. This may change at any moment but I really do think we will heard about that FDA meeting request and it's outcome at the very least. I do feel NTVA will have much to say, show, and help stabilize the share price.
Have a great day. Looks like we might have another day or so of "fun"
The most any private placement holder has paid is 50 cents a share. I wouldn't say awful by any means... 80k shares of 2.12 million shares newly available to trade... Not awful... 38k shares sold before the 8k went out. It's just some people shorting/flipping and a few weak hands.
Think about that... and know that private placement holders are holding at these levels in general. These share numbers are not new... Sometime in October slightly over 10 million will be able to be free traded... (doesn't mean they will be but could be)
We have needed liquidity and this is helping to get us there. The company is smart and have been working for a year and half without many product/research relevant updates. Likely a lot to be made public to bring attention to the company and establish a solid value higher than this with share volume to support.
Fly under the radar until it's time to lift off.
2.12 million shares just became available. We have traded 36k today. Definitely more selling pressure then buying pressure but obviously the holders of these new shares are not going to let them go very cheap.... "yes some small shareholders let them go but not many"
I expect to hear much more news to driving interest in the company and move share price back up. Glad to see some volume even though I've seen a temporary hit to the portfolio.
Sweet... Their muscular research is showing promise or they wouldn't bring in such a renowned expert. Big things will happen here. I expect to hear updates on some of their current findings and possibly applications and contracts (Specifically for their chemical warfare treatment). How awesome would it be to cut a deal with various country military.
On a non-serious note: Gives a whole new meaning to "Get High with Space Force"
No they had no need to have a ton of shares out there at this point. It would not make sense... this is a baby company and I would venture they have had a lot going on behind the scene and will bring that forth once more shares hit the market. If others buy a ton of these discount shares then it will lock up the shares again and back to 4 bucks we go with no news
The amount of free floating shares was 1000 times larger than what it was suppose to be originally after the R/M. Can't help it if the free floating shares were locked up by shareholders. Just give it a week or two and we will have more liquidity and will have some great updates (This is only my speculation) that will help bring attention to the stock.